Humacyte, Inc. (NASDAQ:HUMA) Receives $13.00 Consensus Target Price from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given an average rating of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $13.43.

HUMA has been the subject of several recent research reports. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Friday.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $4.64 on Thursday. The firm has a market cap of $583.99 million, a PE ratio of -3.46 and a beta of 1.38. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 12-month low of $2.48 and a 12-month high of $9.97. The company’s 50 day moving average price is $4.83 and its two-hundred day moving average price is $5.84.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,500,000 shares of company stock valued at $6,606,799. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. nVerses Capital LLC purchased a new position in Humacyte during the second quarter worth about $28,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte during the third quarter worth about $75,000. Principal Financial Group Inc. purchased a new position in shares of Humacyte in the second quarter valued at approximately $83,000. FORA Capital LLC acquired a new position in shares of Humacyte in the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in Humacyte during the 2nd quarter worth approximately $97,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.